A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors

Inclusion Criteria: 1. Male or female from 18 to 80 year-old 2. Patients with advanced clear cellrenal cell carcinoma or von Hippel-Lindau Syndrome associated tumors 3. Has an Eastern Cooperative Oncology Group performance status of 0-1 4. Has a life expectancy of ≥ 12 weeks 5. Should use adequate contraceptive measures throughout the study 6. Females subject must not be pregnant at screening 7. Has the ability to understand and willingness to sign a written informed consent before the performance of the study. Exclusion Criteria: 1. Recieved or being received treatment as follows: 1. Hypoxia-induced factor inhibitors 2. Traditional Chinese medicine indicated for tumors within 2 weeks prior to the first dose of study treatment. 3. Cytotoxic chemotherapeutic drugs, investigational drugs or other systematic anti-tumor therapies within 3 weeks before the first dose of study treatment 4. Colony-stimulating factors (CSFs) within 4 weeks before the first dose of study treatment 5. Local radiotherapy within 2 weeks prior to the first dose of study treatment; more than 30% of bone marrow radiotherapy or large-area irradiation within 4 weeks before the first dose of study treatment. 6. Major surgery within 4 weeks prior to the first dose of study treatment. 2. Has a pulse oximetry reading less than 92% at screening, requires intermittent supplemental oxygen, or requires chronic supplemental oxygen 3. Has failed to recover from a ≥ grade 2 adverse event due to prior anti-tumor therapy 4. Has another malignancy or a history of another non-VHL syndrome associated malignancy 5. Has inadequate bone marrow reserve or organ dysfunction 6. Has a clinically significant bleeding events or tendency within 1 month prior to the first dose of study treatment 7. Has severe infections within 4 weeks prior to the first dose of study treatment 8. Has digestive system diseases may influencing ADME of study drug 9. Has a history of severe hypersensitivity reaction, or proven allergic to HS-10516 or its metabolin 10. Has any disease or condition would compromise subject safety or interfere with study assessments by investigator's decision